Chelation Therapy — CPB 0234 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0234 governing its chelation therapy coverage policy, with an effective date of February 13, 2026. Here's what billing teams need to know before submitting claims.

Chelation therapy has a long history of controversy in payer policy, and Aetna's CPB 0234 sits at the center of that tension. This modification to the Aetna chelation therapy coverage policy puts billing teams on notice — particularly those supporting integrative medicine, cardiology, or toxicology practices that bill chelation-related services. The policy document does not list specific CPT or HCPCS codes in the data available for this update, so if your team is billing chelation therapy, you need to pull the full policy text directly and confirm your code mapping against the current version.

Quick-Reference Table

Aetna Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026

Chelation therapy is one of the more polarizing topics in payer policy. Aetna has maintained that chelation therapy billing hinges almost entirely on the specific clinical indication — what you're treating, and whether the evidence supports it.

The policy distinguishes sharply between chelation for heavy metal poisoning and chelation for everything else. For heavy metal toxicity — think lead poisoning, arsenic exposure, mercury toxicity — Aetna generally recognizes chelation as medically necessary when the clinical picture supports it. These are the indications with legitimate coverage pathways under CPB 0234 in the Aetna system.

On the other side of that line sits cardiovascular disease. Chelation therapy for coronary artery disease, atherosclerosis, or as an alternative to conventional cardiac treatment remains a flash point. Aetna has historically classified this use as experimental and investigational — and this modification does nothing to change that position.

For any covered indication, medical necessity documentation has to be airtight. That means confirmed diagnosis, documented exposure or toxicity levels, and physician-directed treatment plans. Aetna wants to see objective clinical evidence, not just a treating physician's preference for chelation. Prior authorization requirements may apply depending on the specific plan type and indication — confirm with the plan before scheduling treatment.

The real issue here is that the gap between "covered" and "not covered" indications is wider than most billing teams realize. A claim for chelation submitted without the right diagnosis coding — or submitted under a plan that excludes the indication entirely — will result in a claim denial. That's not a recoverable situation without a strong appeal.

Check whether the patient's specific Aetna plan requires prior authorization for chelation services. Commercial plans, Medicare Advantage plans, and self-insured ASO accounts can have materially different coverage rules even within the same payer umbrella.

Aetna Chelation Therapy Exclusions and Non-Covered Indications

This is where most of the financial risk lives. Aetna's coverage policy has consistently treated several chelation therapy uses as experimental, investigational, or unproven. These are the indications most likely to generate automatic claim denials.

Cardiovascular disease and atherosclerosis sit at the top of this list. Despite the TACT trial generating some interest in the cardiology community, Aetna does not consider chelation medically necessary for coronary artery disease. Reimbursement for chelation claims tied to cardiac indications is not available under CPB 0234.

Autism spectrum disorder is another excluded indication. Some practitioners have used chelation therapy under the theory that heavy metal toxicity contributes to autism symptoms. Aetna does not cover this use. Claims submitted with autism-related diagnosis codes as the primary indication will be denied.

Anti-aging, wellness, and detoxification uses are similarly excluded. If your practice markets chelation as a wellness or preventive service, that positioning is incompatible with Aetna's coverage policy — full stop.

Alzheimer's disease and dementia have also been cited historically as non-covered indications for chelation under this type of policy. No peer-reviewed evidence base supports chelation for cognitive decline, and Aetna's position reflects that.

The broader pattern here: if the indication doesn't have strong, peer-reviewed clinical evidence behind it, Aetna's position is that chelation is experimental. That's the framework driving CPB 0234, and this 2026 modification doesn't disrupt it.

Coverage Indications at a Glance

Aetna Chelation Therapy Billing Guidelines and Action Items 2026

This modification went live on February 13, 2026. If your team is still using workflows built against the prior version of CPB 0234, update them now.

CPT, HCPCS, and ICD-10 Codes for Chelation Therapy Under CPB 0234

The policy data for this CPB 0234 modification does not include specific CPT, HCPCS, or ICD-10 codes. Do not assume that previously used codes are still valid under the updated policy.

Chelation therapy billing typically involves infusion administration codes and the specific chelating agents — but confirming which codes Aetna recognizes under the current version of CPB 0234 requires pulling the live policy document directly.

What to do: Access the full CPB 0234 policy at app.payerpolicy.org/p/aetna/0234 or through Aetna's provider portal. Cross-reference every code in your chelation charge master against the current policy before your next billing run. If there's any ambiguity about code mapping, contact Aetna's provider relations line for written confirmation.

This is not a situation to resolve by assumption. Chelation therapy billing carries higher-than-average audit risk given the payer's scrutiny of this service category. The documentation burden is real, and the wrong code on the wrong indication is a denial that may not be appealable.